Every 424B that PROFUSA INC WTS (NVACW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NVACW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVACW filings page.
Profusa, Inc. is registering 126,500 shares of common stock issuable upon exercise of Public Warrants and 579,865 shares of common stock for resale by selling stockholders. This mixed offering combines new share issuance with the registration of existing holders’ shares.
The prospectus also covers the resale of 333,333 “Purchase Shares” that Profusa may sell to Ascent under a $100,000,000 equity line of credit, alongside earlier blocks of 119,611 and 562,820 registered shares. As of February 13, 2026, 1,359,374 shares were outstanding, so the 333,333 Purchase Shares would represent about 19.7% of total shares if all were issued.
Profusa may receive up to $100,000,000 in gross proceeds from sales of Purchase Shares to Ascent and up to $200,148,875 from cash exercises of 17,404,250 warrants, though warrant exercise is unlikely at current prices. Net proceeds from the equity line are earmarked primarily for purchasing Bitcoin, subject to a $5,000,000 minimum cash balance, creating both capital access and volatility tied to cryptocurrency prices.
Profusa, Inc. filed a prospectus supplement covering the resale of up to 567,920 shares of common stock by selling stockholders. These include up to 562,820 "Purchase Shares" that Profusa may sell to Ascent Partners Fund LLC under an equity line of credit and 5,100 shares issued for Business Combination costs, with Profusa potentially receiving up to $100,000,000 in gross proceeds from sales of Purchase Shares to Ascent.
The supplement also incorporates two Form 8-Ks. Profusa received Nasdaq notices that its market value of listed securities and bid price no longer satisfy Global Market standards, and it has until March 10, 2026 to regain compliance. Separately, stockholders approved, and the company implemented, a 1-for-75 reverse stock split effective February 9, 2026, reducing common shares outstanding from about 92.4 million to about 1.2 million while keeping 601 million shares authorized.
Profusa, Inc. filed a prospectus supplement covering the resale of up to 2,962,962 shares of common stock, issuable to Ascent Partners Fund LLC upon conversion of convertible promissory notes with $22,222,222 aggregate principal. These are being offered by the selling stockholder, and Profusa will not receive sale proceeds.
The supplement incorporates recent 8-Ks, including notices that the company no longer meets Nasdaq Global Market requirements for minimum market value of listed securities and for a $1.00 minimum bid, with a compliance period through March 10, 2026. It also reflects a 1-for-75 reverse stock split effective February 9, 2026, which reduced shares outstanding from approximately 92.4 million to about 1.2 million while leaving 601 million authorized shares unchanged.
Profusa, Inc. is registering up to 119,611 shares of common stock for resale by Ascent Partners Fund LLC, including 107,611 Purchase Shares and 12,000 Commitment Warrant Shares tied to an equity line of credit arrangement. Profusa will not receive proceeds from the selling stockholder’s resales, but may receive up to $100,000,000 in gross proceeds from discretionary sales of Purchase Shares to Ascent under the purchase agreement.
The company effected a 1‑for‑75 reverse stock split effective February 9, 2026, reducing common shares outstanding from approximately 92.4 million to approximately 1.2 million, while keeping 601 million shares authorized. All share and per‑share amounts in the supplement are adjusted for this split.
Profusa previously received Nasdaq notices that its market value of listed securities was below $50,000,000 and its bid price below $1.00, triggering a compliance period until March 10, 2026 to regain listing compliance. The company reports continuing net losses, with net loss of $9,230 thousand for 2024 and higher reverse‑split‑adjusted net loss per share figures due to the reduced share count.
Profusa, Inc. updates its equity purchase agreement to temporarily reduce the floor price for certain share sales. Under an amendment signed on December 22, 2025, the Floor Price during a defined “Modification Period” will allow up to 13,650,000 shares of common stock to be issued and sold as Purchased Securities at or above 11.1 cents ($0.111) per share and below 14 cents ($0.14). After either this share cap is reached or the Modification Period ends, the Floor Price reverts to 14 cents ($0.14), calculated as twenty percent of the July 25, 2025 Official Closing Price, as adjusted for certain corporate actions. The Modification Period runs from the amendment date until, but excluding, the effective date of a reverse stock split that is expected to be presented to stockholders in January 2026 if it becomes effective. Profusa’s common stock trades on the Nasdaq Global Market under “PFSA,” with a last sale price of $0.087 per share and 86,414,295 shares outstanding as of December 22, 2025.
Profusa, Inc. filed a 424(b)(3) prospectus to register the resale of up to 42,594,048 shares of common stock. This includes 42,211,548 shares that the company may, at its discretion, sell to Ascent Partners Fund LLC under a committed equity facility and 382,500 shares issued to certain parties for business-combination transaction costs. The selling stockholders may sell from time to time at market or negotiated prices; Ascent is deemed an underwriter.
The company will not receive proceeds from selling stockholder resales. Separately, under the Purchase Agreement, the company may sell shares to Ascent for up to $100,000,000, with purchases priced at 97% of the lowest VWAP over a valuation period, subject to a 9.99% beneficial ownership cap and an exchange cap generally at 19.9%.
Shares outstanding were 41,759,307 as of October 8, 2025. If all 42,211,548 Purchase Shares were issued and outstanding, they would represent approximately 50.3% of total shares and 54.7% of non‑affiliate shares as of that date.